- Home
- DXR vs BDSX Comparison
DXR vs BDSX Comparison
Compare DXR & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- BDSX
- Stock Information
- Founded
- DXR 1970
- BDSX 2005
- Country
- DXR United States
- BDSX United States
- Employees
- DXR N/A
- BDSX N/A
- Industry
- DXR Medical/Dental Instruments
- BDSX Precision Instruments
- Sector
- DXR Health Care
- BDSX Health Care
- Exchange
- DXR Nasdaq
- BDSX Nasdaq
- Market Cap
- DXR 46.9M
- BDSX 53.0M
- IPO Year
- DXR N/A
- BDSX 2020
- Fundamental
- Price
- DXR $12.76
- BDSX $7.61
- Analyst Decision
- DXR Strong Buy
- BDSX Strong Buy
- Analyst Count
- DXR 1
- BDSX 5
- Target Price
- DXR $25.00
- BDSX $32.50
- AVG Volume (30 Days)
- DXR 6.0K
- BDSX 291.8K
- Earning Date
- DXR 01-01-0001
- BDSX 11-03-2025
- Dividend Yield
- DXR N/A
- BDSX N/A
- EPS Growth
- DXR 3.46
- BDSX N/A
- EPS
- DXR 0.36
- BDSX N/A
- Revenue
- DXR $66,306.00
- BDSX $80,173,000.00
- Revenue This Year
- DXR N/A
- BDSX $19.04
- Revenue Next Year
- DXR N/A
- BDSX $26.39
- P/E Ratio
- DXR $36.30
- BDSX N/A
- Revenue Growth
- DXR N/A
- BDSX 22.29
- 52 Week Low
- DXR $6.55
- BDSX $3.44
- 52 Week High
- DXR $14.00
- BDSX $32.20
- Technical
- Relative Strength Index (RSI)
- DXR 48.62
- BDSX 59.98
- Support Level
- DXR $11.81
- BDSX $6.19
- Resistance Level
- DXR $13.50
- BDSX $7.79
- Average True Range (ATR)
- DXR 0.70
- BDSX 0.73
- MACD
- DXR -0.08
- BDSX -0.05
- Stochastic Oscillator
- DXR 54.99
- BDSX 85.16
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.